Published in Br J Pharmacol on May 08, 2006
The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev (2010) 4.31
Genetic dissection of behavioural and autonomic effects of Delta(9)-tetrahydrocannabinol in mice. PLoS Biol (2007) 2.08
Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes. Pharmacol Rev (2010) 1.89
Multiple functions of endocannabinoid signaling in the brain. Annu Rev Neurosci (2012) 1.60
CB2 receptor-mediated migration of immune cells: it can go either way. Br J Pharmacol (2007) 1.55
Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology (2011) 1.50
A day in the life of a G protein-coupled receptor: the contribution to function of G protein-coupled receptor dimerization. Br J Pharmacol (2007) 1.47
Regulation of CB1 cannabinoid receptor trafficking by the adaptor protein AP-3. FASEB J (2008) 1.40
Exploring a role for heteromerization in GPCR signalling specificity. Biochem J (2011) 1.31
G protein-coupled receptor heteromerization: a role in allosteric modulation of ligand binding. Mol Pharmacol (2011) 1.27
Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery? Br J Pharmacol (2010) 1.19
Augmentation of spinal morphine analgesia and inhibition of tolerance by low doses of mu- and delta-opioid receptor antagonists. Br J Pharmacol (2007) 1.15
Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal. Neuroscience (2013) 1.14
The prevalence, maintenance, and relevance of G protein-coupled receptor oligomerization. Mol Pharmacol (2013) 1.14
β2-Adrenergic receptor signaling in the cardiac myocyte is modulated by interactions with CXCR4. J Cardiovasc Pharmacol (2010) 1.08
Wiring and firing neuronal networks: endocannabinoids take center stage. Curr Opin Neurobiol (2008) 1.08
Characterization of cannabinoid-1 receptors in the locus coeruleus: relationship with mu-opioid receptors. Brain Res (2009) 1.07
Receptor-regulated interaction of activator of G-protein signaling-4 and Galphai. J Biol Chem (2010) 1.07
G-protein-coupled receptor heteromers: function and ligand pharmacology. Br J Pharmacol (2007) 1.07
Looking for the role of cannabinoid receptor heteromers in striatal function. Neuropharmacology (2008) 1.06
Regulation of the AGS3·G{alpha}i signaling complex by a seven-transmembrane span receptor. J Biol Chem (2010) 1.06
Interactions between Delta(9)-tetrahydrocannabinol and mu opioid receptor agonists in rhesus monkeys: discrimination and antinociception. Psychopharmacology (Berl) (2008) 1.06
Induced association of mu opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands. J Med Chem (2009) 1.06
Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. Br J Pharmacol (2007) 1.05
Differential response to morphine of the oligomeric state of μ-opioid in the presence of δ-opioid receptors. Biochemistry (2011) 1.03
Agonist-dependent mu-opioid receptor signaling can lead to heterologous desensitization. Cell Signal (2010) 1.03
Physical and functional interaction between CB1 cannabinoid receptors and beta2-adrenoceptors. Br J Pharmacol (2010) 1.02
The complications of promiscuity: endocannabinoid action and metabolism. Br J Pharmacol (2007) 1.02
Cannabinoid-opioid interactions during neuropathic pain and analgesia. Curr Opin Pharmacol (2009) 1.02
Signal transduction via cannabinoid receptors. CNS Neurol Disord Drug Targets (2009) 0.99
The cannabinoid delta-9-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES/CCL5: linkage to the CB2 receptor. J Neuroimmune Pharmacol (2007) 0.96
The mu-opioid receptor agonist morphine, but not agonists at delta- or kappa-opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors. Br J Pharmacol (2008) 0.95
Opioid receptor heteromers in analgesia. Expert Rev Mol Med (2012) 0.94
Heteromultimerization of cannabinoid CB(1) receptor and orexin OX(1) receptor generates a unique complex in which both protomers are regulated by orexin A. J Biol Chem (2011) 0.93
Endogenous opiates and behavior: 2006. Peptides (2007) 0.92
Central antinociception induced by mu-opioid receptor agonist morphine, but not delta- or kappa-, is mediated by cannabinoid CB1 receptor. Br J Pharmacol (2009) 0.92
Receptor heteromerization expands the repertoire of cannabinoid signaling in rodent neurons. PLoS One (2012) 0.91
Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives. J Gastroenterol (2013) 0.91
Gi/o-coupled receptors compete for signaling to adenylyl cyclase in SH-SY5Y cells and reduce opioid-mediated cAMP overshoot. Mol Pharmacol (2010) 0.90
Molecular model of cannabis sensitivity in developing neuronal circuits. Trends Pharmacol Sci (2011) 0.90
Antibodies against G-protein coupled receptors: novel uses in screening and drug development. Comb Chem High Throughput Screen (2008) 0.89
Structural analysis of the human cannabinoid receptor one carboxyl-terminus identifies two amphipathic helices. Biopolymers (2009) 0.89
AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies. Neuropharmacology (2012) 0.89
G Protein-Coupled Receptor Heteromers. Annu Rev Pharmacol Toxicol (2015) 0.88
Morphine modulation of thrombospondin levels in astrocytes and its implications for neurite outgrowth and synapse formation. J Biol Chem (2010) 0.88
GPR171 is a hypothalamic G protein-coupled receptor for BigLEN, a neuropeptide involved in feeding. Proc Natl Acad Sci U S A (2013) 0.87
Opportunities for functional selectivity in GPCR antibodies. Biochem Pharmacol (2012) 0.86
Distinctions among GABAA and GABAB responses revealed by calcium channel antagonists, cannabinoids, opioids, and synaptic plasticity in rat hippocampus. Psychopharmacology (Berl) (2007) 0.84
Interactions between Δ(9)-tetrahydrocannabinol and heroin: self-administration in rhesus monkeys. Behav Pharmacol (2012) 0.84
Revolution in GPCR signalling: opioid receptor heteromers as novel therapeutic targets: IUPHAR review 10. Br J Pharmacol (2014) 0.84
Bivalent ligands that target μ opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance. J Med Chem (2013) 0.84
Dimerization with cannabinoid receptors allosterically modulates delta opioid receptor activity during neuropathic pain. PLoS One (2012) 0.83
Impact of efficacy at the μ-opioid receptor on antinociceptive effects of combinations of μ-opioid receptor agonists and cannabinoid receptor agonists. J Pharmacol Exp Ther (2014) 0.83
CB1 receptors modulate the intake of a sweetened-fat diet in response to μ-opioid receptor stimulation of the nucleus accumbens. Pharmacol Biochem Behav (2010) 0.83
Targeting CB2-GPR55 receptor heteromers modulates cancer cell signaling. J Biol Chem (2014) 0.83
Cannabinoid receptor CB1 regulates STAT3 activity and its expression dictates the responsiveness to SR141716 treatment in human glioma patients' cells. Oncotarget (2015) 0.83
Functional diversity on synaptic plasticity mediated by endocannabinoids. Philos Trans R Soc Lond B Biol Sci (2012) 0.82
Antibodies to probe endogenous G protein-coupled receptor heteromer expression, regulation, and function. Front Pharmacol (2014) 0.82
Opioid and cannabinoid receptors: friends with benefits or just close friends? Br J Pharmacol (2006) 0.82
Low dose naloxone attenuates the pruritic but not anorectic response to rimonabant in male rats. Psychopharmacology (Berl) (2012) 0.81
Consequences of opioid receptor mutation on actions of univalent and bivalent kappa and delta ligands. Psychopharmacology (Berl) (2010) 0.81
PnPP-19, a spider toxin peptide, induces peripheral antinociception through opioid and cannabinoid receptors and inhibition of neutral endopeptidase. Br J Pharmacol (2016) 0.80
Heterodimerization of apelin receptor and neurotensin receptor 1 induces phosphorylation of ERK(1/2) and cell proliferation via Gαq-mediated mechanism. J Cell Mol Med (2014) 0.80
Salvinorin A reduces mechanical allodynia and spinal neuronal hyperexcitability induced by peripheral formalin injection. Mol Pain (2012) 0.80
G-protein-coupled heteromers: regulation in disease. Methods Enzymol (2013) 0.80
In vivo opioid receptor heteromerization: where do we stand? Br J Pharmacol (2014) 0.80
Disease-specific heteromerization of G-protein-coupled receptors that target drugs of abuse. Prog Mol Biol Transl Sci (2013) 0.80
Involvement of opioid system in cognitive deficits induced by ∆⁹-tetrahydrocannabinol in rats. Psychopharmacology (Berl) (2011) 0.80
Functional characterization of G-protein-coupled receptors: a bioinformatics approach. Neuroscience (2014) 0.80
Molecular Pharmacology of δ-Opioid Receptors. Pharmacol Rev (2016) 0.80
Role of antibodies in developing drugs that target G-protein-coupled receptor dimers. Mt Sinai J Med (2010) 0.79
Monoglyceride lipase deficiency causes desensitization of intestinal cannabinoid receptor type 1 and increased colonic μ-opioid receptor sensitivity. Br J Pharmacol (2015) 0.79
The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain. Neuropsychopharmacology (2017) 0.78
Antinociceptive action of isolated mitragynine from Mitragyna Speciosa through activation of opioid receptor system. Int J Mol Sci (2012) 0.78
On the g-protein-coupled receptor heteromers and their allosteric receptor-receptor interactions in the central nervous system: focus on their role in pain modulation. Evid Based Complement Alternat Med (2013) 0.78
Biological Significance of GPCR Heteromerization in the Neuro-Endocrine System. Front Endocrinol (Lausanne) (2011) 0.78
Functions of the chemokine receptor CXCR4 in the central nervous system and its regulation by μ-opioid receptors. Int Rev Neurobiol (2014) 0.78
The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice. Neuropharmacology (2016) 0.77
Pharmacological Profiles of Oligomerized μ-Opioid Receptors. Cells (2013) 0.77
Naltrexone Maintenance Decreases Cannabis Self-Administration and Subjective Effects in Daily Cannabis Smokers. Neuropsychopharmacology (2015) 0.77
Receptor and channel heteromers as pain targets. Pharmaceuticals (Basel) (2012) 0.77
The cannabinoid receptor agonists, anandamide and WIN 55,212-2, do not directly affect mu opioid receptors expressed in Xenopus oocytes. Naunyn Schmiedebergs Arch Pharmacol (2007) 0.77
Functional activity of the cannabinoid 1 receptor is not affected by opioid antagonists in the rat brain. Korean J Anesthesiol (2013) 0.77
Constitutive activity at the cannabinoid CB(1) receptor and behavioral responses. Methods Enzymol (2010) 0.76
Gi-protein-coupled 5-HT1B/D receptor agonist sumatriptan induces type I hyperalgesic priming. Pain (2016) 0.76
Interactions between cannabinoid receptor agonists and mu opioid receptor agonists in rhesus monkeys discriminating fentanyl. Eur J Pharmacol (2016) 0.75
Methods used to study the oligomeric structure of G protein-coupled receptors. Biosci Rep (2017) 0.75
Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans. Drug Alcohol Depend (2016) 0.75
Tolerance to the Diuretic Effects of Cannabinoids and Cross-Tolerance to a κ-Opioid Agonist in THC-Treated Mice. J Pharmacol Exp Ther (2016) 0.75
Blockade of neuronal dopamine D2 receptor attenuates morphine tolerance in mice spinal cord. Sci Rep (2016) 0.75
Acute and chronic mu opioids differentially regulate thrombospondins 1 and 2 isoforms in astrocytes. ACS Chem Neurosci (2013) 0.75
A spider derived peptide, PnPP-19, induces central antinociception mediated by opioid and cannabinoid systems. J Venom Anim Toxins Incl Trop Dis (2016) 0.75
Interacting Cannabinoid and Opioid Receptors in the Nucleus Accumbens Core Control Adolescent Social Play. Front Behav Neurosci (2016) 0.75
International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev (2002) 8.50
Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature (2000) 6.58
Heterodimerization is required for the formation of a functional GABA(B) receptor. Nature (1998) 5.59
Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science (1999) 4.31
Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. Annu Rev Pharmacol Toxicol (2002) 3.45
A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proc Natl Acad Sci U S A (2004) 3.00
The fourth transmembrane segment forms the interface of the dopamine D2 receptor homodimer. J Biol Chem (2002) 2.75
Closed state of both binding domains of homodimeric mGlu receptors is required for full activity. Nat Struct Mol Biol (2004) 2.58
Structure-based analysis of GPCR function: evidence for a novel pentameric assembly between the dimeric leukotriene B4 receptor BLT1 and the G-protein. J Mol Biol (2003) 2.57
International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev (1996) 2.43
Crosstalk in G protein-coupled receptors: changes at the transmembrane homodimer interface determine activation. Proc Natl Acad Sci U S A (2005) 2.33
The G protein-coupled receptor rhodopsin in the native membrane. FEBS Lett (2004) 2.19
G-protein-coupled receptor dimerization: modulation of receptor function. Pharmacol Ther (2002) 2.18
A concept for G protein activation by G protein-coupled receptor dimers: the transducin/rhodopsin interface. Photochem Photobiol Sci (2004) 1.92
Oligomerization of opioid receptors with beta 2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation. Proc Natl Acad Sci U S A (2001) 1.82
Redistribution of GABAB(1) protein and atypical GABAB responses in GABAB(2)-deficient mice. J Neurosci (2004) 1.66
Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. J Neurosci (2001) 1.63
Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci (1999) 1.49
Functional interactions between mu opioid and alpha 2A-adrenergic receptors. Mol Pharmacol (2003) 1.49
Compartment-specific localization of cannabinoid 1 (CB1) and mu-opioid receptors in rat nucleus accumbens. Neuroscience (2004) 1.36
Synergistic interactions between cannabinoid and opioid analgesics. Life Sci (2004) 1.35
Cannabinoid receptor-induced neurite outgrowth is mediated by Rap1 activation through G(alpha)o/i-triggered proteasomal degradation of Rap1GAPII. J Biol Chem (2005) 1.32
Dimerization of G protein-coupled receptors: CB1 cannabinoid receptors as an example. Chem Phys Lipids (2002) 1.30
The G alpha(o/i)-coupled cannabinoid receptor-mediated neurite outgrowth involves Rap regulation of Src and Stat3. J Biol Chem (2005) 1.25
Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J Neurosci (2002) 1.24
Agonist-specific transactivation of phosphoinositide 3-kinase signaling pathway mediated by the dopamine D2 receptor. J Biol Chem (2003) 1.18
Oligomerization of opioid receptors. Methods (2002) 1.17
Serotonin receptor activation leads to neurite outgrowth and neuronal survival. Brain Res Mol Brain Res (2005) 1.14
The CB1 cannabinoid receptor can sequester G-proteins, making them unavailable to couple to other receptors. J Neurosci (1999) 1.12
Allosteric modulators of G-protein-coupled receptors. Curr Opin Pharmacol (2003) 1.12
CB1-cannabinoid and mu-opioid receptor co-localization on postsynaptic target in the rat dorsal horn. Neuroreport (2001) 1.09
Interactions between delta opioid receptors and alpha-adrenoceptors. Clin Exp Pharmacol Physiol (2004) 1.02
Modulation of rat brain opioid receptors by cannabinoids. J Pharmacol Exp Ther (1987) 0.99
Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines. Biochem J (2003) 0.97
Differential roles of ERK and JNK in early and late stages of neuritogenesis: a study in a novel PC12 model system. J Neurochem (2003) 0.89
c-Src protein tyrosine kinase activity is required for muscarinic receptor-mediated DNA synthesis and neurogenesis via ERK1/2 and c-AMP-responsive element-binding protein signaling in neural precursor cells. J Neurosci Res (2003) 0.86
Monoclonal antibody to the delta opioid receptor acts as an agonist in dual regulation of adenylate cyclase in NG108-15 cells. FEBS Lett (1999) 0.86
Delta opioid receptors in human neuroblastoma cell lines. Brain Res (1986) 0.80
Interaction of opioid drugs with human platelet alpha 2-adrenoceptors. Eur J Pharmacol (1992) 0.79
A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proc Natl Acad Sci U S A (2004) 3.00
Building a new conceptual framework for receptor heteromers. Nat Chem Biol (2009) 2.41
D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism. Mol Pharmacol (2007) 2.28
Increased abundance of opioid receptor heteromers after chronic morphine administration. Sci Signal (2010) 1.90
Receptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers. FASEB J (2007) 1.89
G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives. Pharmacol Rev (2014) 1.82
Hemopressin is an inverse agonist of CB1 cannabinoid receptors. Proc Natl Acad Sci U S A (2007) 1.70
The emerging functions of endocannabinoid signaling during CNS development. Trends Pharmacol Sci (2007) 1.68
Systems approach to explore components and interactions in the presynapse. Proteomics (2009) 1.61
Morphine administration alters the profile of hippocampal postsynaptic density-associated proteins: a proteomics study focusing on endocytic proteins. Mol Cell Proteomics (2006) 1.43
Cell surface targeting of mu-delta opioid receptor heterodimers by RTP4. Proc Natl Acad Sci U S A (2008) 1.42
Regulation of CB1 cannabinoid receptor trafficking by the adaptor protein AP-3. FASEB J (2008) 1.40
Receptor heteromerization and drug discovery. Trends Pharmacol Sci (2010) 1.37
Conformation state-sensitive antibodies to G-protein-coupled receptors. J Biol Chem (2006) 1.37
Identification of a μ-δ opioid receptor heteromer-biased agonist with antinociceptive activity. Proc Natl Acad Sci U S A (2013) 1.34
Cannabinoid receptor-induced neurite outgrowth is mediated by Rap1 activation through G(alpha)o/i-triggered proteasomal degradation of Rap1GAPII. J Biol Chem (2005) 1.32
Exploring a role for heteromerization in GPCR signalling specificity. Biochem J (2011) 1.31
Multiple actions of spinophilin regulate mu opioid receptor function. Neuron (2008) 1.30
Opioid receptor oligomerization. Detection and functional characterization of interacting receptors. Methods Mol Med (2003) 1.28
G protein-coupled receptor heteromerization: a role in allosteric modulation of ligand binding. Mol Pharmacol (2011) 1.27
Novel endogenous peptide agonists of cannabinoid receptors. FASEB J (2009) 1.25
The G alpha(o/i)-coupled cannabinoid receptor-mediated neurite outgrowth involves Rap regulation of Src and Stat3. J Biol Chem (2005) 1.25
AT1R-CB₁R heteromerization reveals a new mechanism for the pathogenic properties of angiotensin II. EMBO J (2011) 1.18
An emerging role for the delta opioid receptor in the regulation of mu opioid receptor function. ScientificWorldJournal (2007) 1.18
Oligomerization of opioid receptors. Methods (2002) 1.17
Serotonin receptor activation leads to neurite outgrowth and neuronal survival. Brain Res Mol Brain Res (2005) 1.14
Endoplasmic reticulum stress induces fibrogenic activity in hepatic stellate cells through autophagy. J Hepatol (2013) 1.12
Neuropeptide processing profile in mice lacking prohormone convertase-1. Biochemistry (2005) 1.09
GPCR-OKB: the G Protein Coupled Receptor Oligomer Knowledge Base. Bioinformatics (2010) 1.09
β2-Adrenergic receptor signaling in the cardiac myocyte is modulated by interactions with CXCR4. J Cardiovasc Pharmacol (2010) 1.08
Grand opening of structure-guided design for novel opioids. Trends Pharmacol Sci (2012) 1.04
Obesity and diabetes in transgenic mice expressing proSAAS. J Endocrinol (2004) 1.04
Cannabinoid receptor 2-mediated attenuation of CXCR4-tropic HIV infection in primary CD4+ T cells. PLoS One (2012) 1.03
Targeting opioid receptor heterodimers: strategies for screening and drug development. AAPS J (2006) 1.02
Interactions between delta opioid receptors and alpha-adrenoceptors. Clin Exp Pharmacol Physiol (2004) 1.02
Inquiry learning. Integrating content detail and critical reasoning by peer review. Science (2008) 1.02
Cannabinoid-opioid interactions during neuropathic pain and analgesia. Curr Opin Pharmacol (2009) 1.02
Allosteric interactions between δ and κ opioid receptors in peripheral sensory neurons. Mol Pharmacol (2011) 1.00
The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications. Pharmacol Rev (2011) 0.99
Modulation of opiate-related signaling molecules in morphine-dependent conditioned behavior: conditioned place preference to morphine induces CREB phosphorylation. Neuropsychopharmacology (2009) 0.99
Hemoglobin-derived peptides as novel type of bioactive signaling molecules. AAPS J (2010) 0.97
Neuroproteomics of the synapse and drug addiction. J Pharmacol Exp Ther (2006) 0.96
The propeptide precursor proSAAS is involved in fetal neuropeptide processing and body weight regulation. J Neurochem (2010) 0.96
Insider access: pepducin symposium explores a new approach to GPCR modulation. Ann N Y Acad Sci (2009) 0.96
Characterization of endothelin-converting enzyme-2. Implication for a role in the nonclassical processing of regulatory peptides. J Biol Chem (2003) 0.94
Peptidomics of Cpefat/fat mouse hypothalamus and striatum: effect of chronic morphine administration. J Mol Neurosci (2006) 0.94
Opioid receptor heteromers in analgesia. Expert Rev Mol Med (2012) 0.94
Processing of proSAAS in neuroendocrine cell lines. Biochem J (2002) 0.93
Teaching resources. Cell signaling systems: a course for graduate students. Sci STKE (2005) 0.93
Structural biology: How opioid drugs bind to receptors. Nature (2012) 0.92
Receptor heteromerization expands the repertoire of cannabinoid signaling in rodent neurons. PLoS One (2012) 0.91
Teaching resources. Using web-based discussion forums as a model of the peer-review process and a tool for assessment. Sci Signal (2008) 0.91
Homology modeling and site-directed mutagenesis to identify selective inhibitors of endothelin-converting enzyme-2. J Med Chem (2008) 0.90
Potentiation of μ-opioid receptor-mediated signaling by ketamine. J Neurochem (2011) 0.90
Antibodies against G-protein coupled receptors: novel uses in screening and drug development. Comb Chem High Throughput Screen (2008) 0.89
Modulation of opioid receptor function by protein-protein interactions. Front Biosci (Landmark Ed) (2009) 0.88
Chronic morphine alters the presynaptic protein profile: identification of novel molecular targets using proteomics and network analysis. PLoS One (2011) 0.88
GPR171 is a hypothalamic G protein-coupled receptor for BigLEN, a neuropeptide involved in feeding. Proc Natl Acad Sci U S A (2013) 0.87
Embryonic gene expression and pro-protein processing of proSAAS during rodent development. J Neurochem (2005) 0.86
Post-activation-mediated changes in opioid receptors detected by N-terminal antibodies. J Biol Chem (2008) 0.86
The use of receptor-specific antibodies to study G-protein-coupled receptors. Mt Sinai J Med (2006) 0.86
Functional relevance of μ-δ opioid receptor heteromerization: a role in novel signaling and implications for the treatment of addiction disorders: from a symposium on new concepts in mu-opioid pharmacology. Drug Alcohol Depend (2011) 0.85
Quantification of VGF- and pro-SAAS-derived peptides in endocrine tissues and the brain, and their regulation by diet and cold stress. Brain Res (2006) 0.84
Revolution in GPCR signalling: opioid receptor heteromers as novel therapeutic targets: IUPHAR review 10. Br J Pharmacol (2014) 0.84
Heteromers of μ-δ opioid receptors: new pharmacology and novel therapeutic possibilities. Br J Pharmacol (2014) 0.83
Possible involvement of prolonging spinal µ-opioid receptor desensitization in the development of antihyperalgesic tolerance to µ-opioids under a neuropathic pain-like state. Addict Biol (2011) 0.83
Dimerization with cannabinoid receptors allosterically modulates delta opioid receptor activity during neuropathic pain. PLoS One (2012) 0.83
Mechanisms of action of antidepressants: from neurotransmitter systems to signaling pathways. Cell Signal (2005) 0.82
Quantitative neuroproteomics of the synapse. Methods Mol Biol (2010) 0.82
G-protein-coupled heteromers: regulation in disease. Methods Enzymol (2013) 0.80
Disease-specific heteromerization of G-protein-coupled receptors that target drugs of abuse. Prog Mol Biol Transl Sci (2013) 0.80
Endothelin converting enzyme-2: a processing enzyme involved in the generation of novel neuropeptides. Protein Pept Lett (2004) 0.80
Role of antibodies in developing drugs that target G-protein-coupled receptor dimers. Mt Sinai J Med (2010) 0.79
Escorts take the lead molecular chaperones as therapeutic targets. Prog Mol Biol Transl Sci (2010) 0.79
An integrated quantitative proteomics and systems biology approach to explore synaptic protein profile changes during morphine exposure. Neuropsychopharmacology (2013) 0.79